Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

William Beck

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Physiology

Anatomy

Disorders

Leukemia

Concepts & Ideas

Molecular Sequence Data

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
17
Mo, Yin-Yuan
16
Danks, Mary
4
Friche, Ellen
4
He, Xiaolong
4
Ee, Pui Lai Rachel
3
Bhat, Uppoor
3
Khélifa, T
3
Morgan, SE
3
Wang, Q
3
Winter, Mark
3
Yu, Yanni
2
Wu, Fangting
2
Ross, Douglas
2
Coon, John
2
Kamalakaran, Sitharthan

Sign-in to see all Coauthors

Publications

TOP 3
Wu Fangting; Zhu Shuomin; Ding Yanna; Beck William T; Mo Yin-Yuan
MicroRNA-mediated regulation of Ubc9 expression in cancer cells.
He X; Pool M; Darcy K M; Lim S B; Auersperg N; Coon J S; Beck W T
Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro.
Wu Fangting; Chiocca Susanna; Beck William T; Mo Yin-Yuan
Gam1-associated alterations of drug responsiveness through activation of apoptosis.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of William Beck (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Wu Fangting; Zhu Shuomin; Ding Yanna; Beck William T; Mo Yin-Yuan
MicroRNA-mediated regulation of Ubc9 expression in cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1550-7.
2007: He X; Pool M; Darcy K M; Lim S B; Auersperg N; Coon J S; Beck W T
Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro.
Oncogene 2007;26(34):4961-8.
2007: Wu Fangting; Chiocca Susanna; Beck William T; Mo Yin-Yuan
Gam1-associated alterations of drug responsiveness through activation of apoptosis.
Molecular cancer therapeutics 2007;6(6):1823-30.
2007: Mirski Shelagh E L; Sparks Kathryn E; Friedrich Beate; Köhler Matthias; Mo Yin-Yuan; Beck William T; Cole Susan P C
Topoisomerase II binds importin alpha isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells.
Experimental cell research 2007;313(3):627-37.
2005: Kamalakaran Sitharthan; Radhakrishnan Senthil K; Beck William T
Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites.
The Journal of biological chemistry 2005;280(22):21491-7.
2005: Mo Yin-Yuan; Yu Yanni; Theodosiou Elena; Ee P L Rachel; Beck William T
A role for Ubc9 in tumorigenesis.
Oncogene 2005;24(16):2677-83.
2004: Ee P L Rachel; He Xiaolong; Ross Douglas D; Beck William T
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
Molecular cancer therapeutics 2004;3(12):1577-83.
2004: He Xiaolong; Ee P L Rachel; Coon John S; Beck William T
Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4652-60.
2004: Mo Yin-Yuan; Yu Yanni; Ee P L Rachel; Beck William T
Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs.
Cancer research 2004;64(8):2793-8.
2004: Ee Pui Lai Rachel; Kamalakaran Sitharthan; Tonetti Debra; He Xiaolong; Ross Douglas D; Beck William T
Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene.
Cancer research 2004;64(4):1247-51.
2002: Rallabhandi Prasad; Hashimoto Keiko; Mo Yin-Yuan; Beck William T; Moitra Prasun K; D'Arpa Peter
Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin.
The Journal of biological chemistry 2002;277(42):40020-6.
2002: Tavormina Penny A; Côme Marie-George; Hudson Joanna R; Mo Yin-Yuan; Beck William T; Gorbsky Gary J
Rapid exchange of mammalian topoisomerase II alpha at kinetochores and chromosome arms in mitosis.
The Journal of cell biology 2002;158(1):23-9.
2002: Mo Yin-Yuan; Yu Yanni; Shen Zhiyuan; Beck William T
Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein.
The Journal of biological chemistry 2002;277(4):2958-64.
2001: Beck W T; Mo Y Y; Bhat U G
Cytotoxic signalling by inhibitors of DNA topoisomerase II.
Biochemical Society transactions 2001;29(Pt 6):702-3.
2001: Morgan S E; Beck W T
Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells.
Molecular pharmacology 2001;59(2):203-11.
2000: Mo Y Y; Wang C; Beck W T
A novel nuclear localization signal in human DNA topoisomerase I.
The Journal of biological chemistry 2000;275(52):41107-13.
2000: Morgan S E; Kim R; Wang P C; Bhat U G; Kusumoto H; Lu T; Beck W T
Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Oncogene 2000;19(43):5010-9.
2000: Mo Y Y; Wang P; Beck W T
Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells.
Experimental cell research 2000;256(2):480-90.
2000: Morgan S E; Cadena R S; Raimondi S C; Beck W T
Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Molecular pharmacology 2000;57(2):296-307.
1999: Mo Y Y; Beck W T
Association of human DNA topoisomerase IIalpha with mitotic chromosomes in mammalian cells is independent of its catalytic activity.
Experimental cell research 1999;252(1):50-62.
1999: Khélifa T; Beck W T
Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells.
Biochemical pharmacology 1999;58(8):1247-57.
1999: Bhat U G; Raychaudhuri P; Beck W T
Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(14):7859-64.
1999: Khélifa T; Beck W T
Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease.
Molecular pharmacology 1999;55(3):548-56.
1999: Mo Y Y; Beck W T
DNA damage signals induction of fas ligand in tumor cells.
Molecular pharmacology 1999;55(2):216-22.
1998: Wang Q; Beck W T
Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.
Cancer research 1998;58(24):5762-9.
1998: Mo Y Y; Ameiss K A; Beck W T
Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein.
BioTechniques 1998;25(6):1052-7.
1997: Mo Y Y; Wang Q; Beck W T
Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Cancer research 1997;57(22):5004-8.
1997: Beck W T; Khélifa T; Kusumoto H; Mo Y Y; Rodgers Q; Wolverton J S; Wang Q
Novel mechanisms of resistance to inhibitors of DNA topoisomerases.
Advances in enzyme regulation 1997;37():17-26.
1997: Mo Y Y; Beck W T
Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.
Oncology research 1997;9(4):193-204.
1996: Nitiss J L; Beck W T
Antitopoisomerase drug action and resistance.
European journal of cancer (Oxford, England : 1990) 1996;32A(6):958-66.
1996: Kusumoto H; Rodgers Q E; Boege F; Raimondi S C; Beck W T
Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Cancer research 1996;56(11):2573-83.
1995: Bhat U G; Winter M A; Pearce H L; Beck W T
A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
Molecular pharmacology 1995;48(4):682-9.
1995: Chen M; Beck W T
Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Cancer research 1995;55(7):1509-16.
1995: Chen M; Beck W T
DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Oncology research 1995;7(2):103-11.
1994: Danks M K; Qiu J; Catapano C V; Schmidt C A; Beck W T; Fernandes D J
Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26.
Biochemical pharmacology 1994;48(9):1785-95.
1994: Kim R; Beck W T
Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Cancer research 1994;54(18):4958-66.
1994: Beck W T; Danks M K; Wolverton J S; Chen M; Granzen B; Kim R; Suttle D P
Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II.
Advances in pharmacology (San Diego, Calif.) 1994;29B():145-69.
1994: Beck W T; Kim R; Chen M
Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S14-8.
1993: Chen M; Beck W T
Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Cancer research 1993;53(24):5946-53.
1993: Gudkov A V; Zelnick C R; Kazarov A R; Thimmapaya R; Suttle D P; Beck W T; Roninson I B
Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(8):3231-5.
1993: Danks M K; Warmoth M R; Friche E; Granzen B; Bugg B Y; Harker W G; Zwelling L A; Futscher B W; Suttle D P; Beck W T
Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Cancer research 1993;53(6):1373-9.
1993: Beck W T; Danks M K; Wolverton J S; Kim R; Chen M
Drug resistance associated with altered DNA topoisomerase II.
Advances in enzyme regulation 1993;33():113-27.
1993: Beck W T; Danks M K; Wolverton J S; Granzen B; Chen M; Schmidt C A; Bugg B Y; Friche E; Suttle D P
Altered DNA topoisomerase II in multidrug resistance.
Cytotechnology 1993;11(2):115-9.
1992: Friche E; Danks M K; Beck W T
Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.
Cancer research 1992;52(20):5701-6.
1992: Wolverton J S; Danks M K; Granzen B; Beck W T
DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
Cancer research 1992;52(15):4248-53.
1992: Beck W T; Qian X D
Photoaffinity substrates for P-glycoprotein.
Biochemical pharmacology 1992;43(1):89-93.
1992: Granzen B; Graves D E; Baguley B C; Danks M K; Beck W T
Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Oncology research 1992;4(11-12):489-96.
1991: Bugg B Y; Danks M K; Beck W T; Suttle D P
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(17):7654-8.
1991: Friche E; Danks M K; Schmidt C A; Beck W T
Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
Cancer research 1991;51(16):4213-8.
1991: Beck W T; Danks M K
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Seminars in cancer biology 1991;2(4):235-44.
1990: Beck W T
Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors.
Cancer treatment reviews 1990;17 Suppl A():11-20.
1990: Qian X D; Beck W T
Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts.
The Journal of biological chemistry 1990;265(31):18753-6.
1990: Beck W T
Multidrug resistance and its circumvention.
European journal of cancer (Oxford, England : 1990) 1990;26(4):513-5.
1990: Qian X D; Beck W T
Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines.
Cancer research 1990;50(4):1132-7.
1990: Thimmaiah K N; Horton J K; Qian X D; Beck W T; Houghton J A; Houghton P J
Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines.
Cancer communications 1990;2(7):249-59.
1990: Beck W T
Strategies to circumvent multidrug resistance due to P-glycoprotein or to altered DNA topoisomerase II.
Bulletin du cancer 1990;77(11):1131-41.
1990: Pearce H L; Winter M A; Beck W T
Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance.
Advances in enzyme regulation 1990;30():357-73.
1989: Beck W T
Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.
Journal of the National Cancer Institute 1989;81(22):1683-5.
1989: Pearce H L; Safa A R; Bach N J; Winter M A; Cirtain M C; Beck W T
Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(13):5128-32.
1989: Wolverton J S; Danks M K; Schmidt C A; Beck W T
Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Cancer research 1989;49(9):2422-6.
1989: Danks M K; Schmidt C A; Deneka D A; Beck W T
Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide.
Cancer communications 1989;1(2):101-9.
1988: Danks M K; Schmidt C A; Cirtain M C; Suttle D P; Beck W T
Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
Biochemistry 1988;27(24):8861-9.
1988: Beck W T; Cirtain M C; Glover C J; Felsted R L; Safa A R
Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine.
Biochemical and biophysical research communications 1988;153(3):959-66.
1988: Zamora J M; Pearce H L; Beck W T
Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.
Molecular pharmacology 1988;33(4):454-62.
1987: Beck W T; Cirtain M C; Danks M K; Felsted R L; Safa A R; Wolverton J S; Suttle D P; Trent J M
Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Cancer research 1987;47(20):5455-60.
1986: Beck W T; Cirtain M C; Ashmun R A; Mirro J
Differentiation and the multiple drug resistance phenotype in human leukemic cells.
Cancer research 1986;46(9):4571-5.
1986: Beck W T; Cirtain M C; Look A T; Ashmun R A
Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Cancer research 1986;46(2):778-84.
1986: Beck W T; Danks M K; Cirtain M C; van Heiningen J N
Cross-resistance patterns and antigen expression in Vinca alkaloid- and other multiple drug-resistant human leukemic cell lines.
Progress in clinical and biological research 1986;223():3-10.
1983: Beck W T; Cirtain M C; Lefko J L
Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Molecular pharmacology 1983;24(3):485-92.
1982: Beck W T; Cirtain M C
Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase.
Cancer research 1982;42(1):184-9.

Sign-in to see more